Revelations and revolutions in the understanding of Parkinson’s disease  by Dawson, Ted M. et al.
Biochimica et Biophysica Acta 1792 (2009) 585–586
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisPreface
Revelations and revolutions in the understanding of Parkinson’s diseaseThe last decade witnessed tremendous advances in understanding
the causes of Parkinson’s disease (PD). The identiﬁcation of mutations
in the α-synuclein gene that cause autosomal-dominant PD by
Nussbaum and colleagues helped usher in the genomic era of disease
research. Subsequent advancements made in genetics, diagnostics,
neuroimaging, pathology and biochemistry have provided clear
reciprocal beneﬁts, where critical observations in one avenue of
research led to breakthroughs in other areas in short order. With this
spirit in mind, we invited investigators involved in diverse aspects of
PD research to contribute their expertise in critically evaluating past
and ongoing studies, and to postulate on future directions and the
prediction of mechanisms underlying pathogenesis, with an emphasis
on issues that we believe warrant special attention.
In this issue, Tom Gasser provides a unique insight into studies
leadingup to the identiﬁcation of genes underlyingMendelian formsof
PD andhow tobest interpretmore recently describedMendelian genes
that have more limited evidence of pathogenecity. In complement,
Bras and Singleton focus on common genetic variation that may
inﬂuence susceptibility to disease and how the application of genome
wide association studies in PD promises to identify new genetic risk
factors. The identiﬁcation of genetic factors important in PD presents
the opportunity for the development of model systems where
biochemical pathways can be deciphered and therapeutic efﬁcacies
tested. Lim and Ng discuss genetic models so far developed and how
they overlap (or diverge) from what might be considered a
representative model of PD.
The two genes linked to dominantly inherited PD, α-synuclein and
LRRK2, have garnered the majority of attention by many investigators
interested in understanding the molecular basis of PD. α-Synuclein
has a strong genetic and pathological association with PD, while
mutations in LRRK2 are the most common known cause of familial
and late-onset PD. Waxman and Giasson discuss the current and
sometimes conﬂicting theories underlying the molecular mechanisms
of α-synuclein-induced neurodegeneration and highlight what is
known about the unexpectedly enigmatic small protein. As a kinase,
LRRK2 is the ﬁrst protein implicated in familial PD that belongs to a
family of proteins already successfully targeted by small molecules to
treat human diseases. Biskup and West discuss potential pathogenic
mechanisms and LRRK2-linked pathways and the evidence thus far
that LRRK2 activity is critical for the development of PD. The activity of
α-synuclein and LRRK2 may be at the heart of disease pathogenesis,
and Zhou and Przedborski consider the intracellular application of
gene-engineered antibodies, or intrabodies, that might interfere with
disease-associated activity.
The biology of neurodegeneration and neurodysfunction is com-
plex, and deciphering events that occur in cells prior to their
disappearance requires innovative and creative approaches. Tsang
and Chung discuss how oxidative and nitrosative stress might
contribute to the pathogenesis of PD with a focus on how stress-0925-4439/$ – see front matter © 2009 Published by Elsevier B.V.
doi:10.1016/j.bbadis.2009.06.001related dysfunction of proteins implicated in familial PD may shed
light on why markers of oxidative and nitrosative stress are
consistently observed in disease. Mitochondrial dysfunction has
been suspected for many years as a potential primary and/or
secondary mediator of neurodegeneration. Banerjee and colleagues
review the evidence for mitochondrial dysfunction in PD and the
interplay of mitochondrial dysfunction with known genetic causes.
Finally, PD might be a disorder of misfolded proteins, and as the
primary defense against the accumulation of misfolded proteins, the
ubiquitin proteasome system has been scrutinized in PDmodels. Cook
and Petrucelli review the evidence that supports the possibility that
the ubiquitin proteasome system may become compromised through
pathogenic mechanisms responsible for PD. As yet, the genes and
biochemical mechanisms implicated in PD have not converged on
common ground that would explain the selective and yet broad
neurodysfunction associated with the disease, but with continued
emphasis on bridging together critical genes and pathways, a more
complete picture will certainly emerge in the future.
Precedent fromother diseases suggests that knowledge of the exact
mechanism of cellular dysfunction may not be a requirement for the
development of efﬁcacious neuroprotective strategies. Yacoubian and
Standaert provide a comprehensive evaluation of efforts to identify
neuroprotective therapies in PD, and how past trials that failed to
demonstrate neuroprotection help to further understand the origins of
the disease. Wijeyekoon and Barker discuss neurorestorative
approaches for PD based on the use of cell replacement therapy that
may include embryonic stem cells and induced pluripotent stem cells.
Finally, PD has been on the forefront with regard to the utilization of
emergent technologies in gene therapy approaches. Björklund and
Kirik comment on the different approaches for gene therapy that
promise to provide both neuroprotection and neurorestoration in PD.
Clearly the etiology of PD is not fully understood. Jang and
colleagues consider the role of inﬂuenza viruses and other viruses in
the development of parkinsonism, a particularly timely discussion due
to the continual emergence of new inﬂuenza strains. Jang and
colleagues hypothesize that certain viral infections may predispose
individuals with particular genetic backgrounds to PD.
As a greater understanding of PD is developed through molecular
investigations and as new therapies are tested and developed, there is
an important need to monitor PD progression and identify cases early
in the disease process. Accordingly, Pavese and Brooks discuss past
and future imaging methods to study both motor and nonmotor
complications associated with PD. On a pathological level, Dr. Jellinger
reviews the current staging of α-synuclein pathology in Lewy body
disorders, including PD, Lewy body disease, and dementia with Lewy
Bodies. He presents a strong argument that dementia in PD often does
not correlate with proposed stages of Lewy body pathology,
fundamentally highlighting that the pathogenic role of Lewy bodies
has not yet been elucidated.
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586 PrefaceThe reader should note that this collection of papers only
represents a portion of the outstanding work ongoing in PD research.
All the work highlighted here would not have been possible without
the extensive body of work that preceded these studies. Due to space
limitations and timing, it is not possible to acknowledge all the past
and ongoing work in PD. We hope this special issue provides a taste of
the excitement in this ﬁeld and the opportunities for innovative
therapies that are arising. Finally, we thank all the contributors for
their timely contributions and the expert reviewers for their advice
and guidance on these articles.
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